Novel vasocontractile role of the P2Y14 receptor: Characterization of its signalling in porcine isolated pancreatic arteries

British Journal of Pharmacology

Volumn 171, Issue 3, 2014, Pages 701-713

  Alsaqati, M ^a   Latif, M L ^a   Chan, S L F ^a   Ralevic, V ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

endothelium; MRS2690; P2Y14 receptor; UDP; UDP glucose; vasoconstriction

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 2 NAPHTHOIC ACID DERIVATIVE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 4 [ 4 (PIPERIDIN 4 YL)PHENYL] 7 [4 (TRIFLUOROMETHYL)PHENYL] 2 NAPHTHOIC ACID; CYCLIC AMP; ENDOTHELIN 1; FORSKOLIN; G PROTEIN COUPLED RECEPTOR; MRS2578; MRS2690; MYOSIN LIGHT CHAIN; NIFEDIPINE; PROSTAGLANDIN F2 ALPHA; PURINERGIC P2Y RECEPTOR; PURINERGIC P2Y14 RECEPTOR; PURINERGIC P2Y6 RECEPTOR; SUBSTANCE P; THROMBOXANE A2; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE GLUCOSE; URIDINE TRIPHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; ENZYME IMMUNOASSAY; FEMALE; MALE; MUSCLE ISOMETRIC CONTRACTION; NONHUMAN; PANCREAS; PANCREAS ARTERY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SWINE; WESTERN BLOTTING;

ENDOTHELIUM; MRS2690; P2Y14 RECEPTOR; UDP; UDP-GLUCOSE; VASOCONSTRICTION;

ANIMALS; ARTERIES; CALCIUM CHANNEL BLOCKERS; CALCIUM SIGNALING; CYCLIC AMP; ENDOTHELIUM, VASCULAR; FEMALE; MALE; MUSCLE, SMOOTH, VASCULAR; NERVE TISSUE PROTEINS; PANCREAS; PROTEIN ISOFORMS; PURINERGIC P2Y RECEPTOR AGONISTS; RECEPTORS, PURINERGIC P2Y; RECOMBINANT PROTEINS; SECOND MESSENGER SYSTEMS; SUS SCROFA; URIDINE DIPHOSPHATE GLUCOSE; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASOMOTOR SYSTEM;

EID: 84891120218     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12473     Document Type: Article

References (45)

1. 14 receptor agonists, UDP-glucose and MRS2690, on porcine coronary artery contractility. Available at: http://www.pA2online.org/abstracts/Vol9Issue3abst051p.pdf (accessed 4/9/2012).
2. Abbracchio MP, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, Miras-Portugal MT, et al. (2003). Characterization of the UDP-glucose receptor (re-named here the P2Y14 receptor) adds diversity to the P2Y receptor family. Trends Pharmacol Sci 24: 52-55.
3. Abbracchio MP, Burnstock G, Boeynaems J-M, Barnard EA, Boyer JL, Kennedy C, et al. (2006). International union of pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol Rev 58: 281-341.
4. Alexander SPH, et al. (2013). The Concise Guide to PHARMACOLOGY 2013/14: Overview. Br J Pharmacol 170: 1449-1867.
5. 14 receptor in porcine isolated pancreatic arteries. Available at: http://www.pa2online.org/abstracts/vol8issue1abst028p.pdf (accessed 4/9/2012).
6. Amano M, Ito M, Kimura K, Fukata Y, Chihara K, Nakano T, et al. (1996). Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J Biol Chem 271: 20246-20249.
7. Barrett MO, Sesma JI, Ball CB, Jayasekara PS, Jacobson KA, Lazarowski ER, et al. (2013). Selective high-affinity antagonist of the P2Y14 receptor inhibits UDP-glucose-stimulated chemotaxis of human neutrophils. Mol Pharmacol 84: 41-49.
8. Burnstock G, Novak I, (2012). Purinergic signalling in the pancreas in health and disease. J Endocrinol 213: 123-141.
9. Carter RL, Fricks IP, Barrett MO, Burianek LE, Zhou Y, Ko H, et al. (2009). Quantification of Gi-mediated inhibition of adenylyl cyclase activity reveals that UDP is a potent agonist of the human P2Y14 receptor. Mol Pharmacol 76: 1341-1348.
10. Chambers JK, Macdonald LE, Sarau HM, Ames RS, Freeman K, Foley JJ, et al. (2000). A G protein-coupled receptor for UDP-glucose. J Biol Chem 275: 10767-10771.
11. Chootip K, Gurney AM, Kennedy C, (2005). Multiple P2Y receptors couple to calcium-dependent, chloride channels in smooth muscle cells of the rat pulmonary artery. Respir Res 6: 124.
12. Fabiato A, (1983). Calcium-induced release of calcium from the cardiac sarcoplasmic reticulum. Am J Physiol 245: C1-C14.
13. Fricks IP, Maddileti S, Carter RL, Lazarowski ER, Nicholas RA, Jacobson KA, et al. (2008). UDP is a competitive antagonist at the human P2Y14 receptor. J Pharmacol Exp Ther 325: 588-594.
14. Gao ZG, Ding Y, Jacobson KA, (2010). UDP-glucose acting at P2Y14 receptors is a mediator of mast cell degranulation. Biochem Pharmacol 79: 873-879.
15. Govindan S, Taylor EJ, Taylor CW, (2010). Ca(2+) signalling by P2Y receptors in cultured rat aortic smooth muscle cells. Br J Pharmacol 160: 1953-1962.
16. Harden TK, Sesma JI, Fricks IP, Lazarowski ER, (2010). Signalling and pharmacological properties of the P2Y receptor. Acta Physiol (Oxf) 199: 149-160.
17. Hartshorne DJ, Gorecka A, (2011). Biochemistry of the contractile proteins of smooth muscle. In:, Terjung R, (ed.). Comprehensive Physiology. Chapter 4, John Wiley & Sons: Hoboken, pp. 93-120.
18. Hillaire-Buys D, Chapal J, Petit P, Loubatières-Mariani M-M, (1991). Dual regulation of pancreatic vascular tone by P2X and P2Y purinoceptor subtypes. Eur J Pharmacol 199: 309-314.
19. 12 antagonist AZD6140 inhibits ADP-induced contractions in murine and human vasculature. Int J Cardiol 142: 187-192.
20. Jacobson KA, Ivanov AA, de Castro S, Harden TK, Ko H, (2009). Development of selective agonists and antagonists of P2Y receptors. Purinergic Signal 5: 75-89.
21. Kauffenstein G, Drouin A, Thorin-Trescases N, Bachelard H, Robaye B, D'Orléans-Juste P, et al. (2010). NTPDase1 (CD39) controls nucleotide-dependent vasoconstriction in mouse. Cardiovasc Res 85: 204-213.
22. Ko H, Das A, Carter RL, Fricks IP, Zhou Y, Ivanov AA, et al. (2009). Molecular recognition in the P2Y(14) receptor: probing the structurally permissive terminal sugar moiety of uridine-5′-diphosphoglucose. Bioorg Med Chem 17: 5298-5311.
23. von Kügelgen I, (2006). Pharmacological profiles of cloned mammalian P2Y-receptor subtypes. Pharmacol Ther 110: 415-432.
24. Kurahashi K, Nishihashi T, Trandafir CC, Wang AM, Murakami S, Ji X, (2003). Diversity of endothelium-derived vasocontracting factors-arachidonic acid metabolites. Acta Pharmacol Sin 24: 1065-1069.
25. Lazarowski ER, Shea DA, Boucher RC, Harden TK, (2003). Release of cellular UDP-glucose as a potential extracellular signalling molecule. Mol Pharmacol 63: 1190-1197.
26. Li N, Sul JY, Haydon PG, (2003). A calcium-induced calcium influx factor, nitric oxide, modulates the refilling of calcium stores in astrocytes. J Neurosci 23: 10302-10310.
27. 2+ signaling and proliferative responses in pulmonary artery vasa vasorum endothelial cells. Am J Physiol Cell Physiol 300: C266-C275.
28. 6 nucleotide receptors. Biochem Pharmacol 67: 1763-1770.
29. Mombouli JV, Vanhoutte PM, (1993). Purinergic endothelium-dependent and -independent contractions in rat aorta. Hypertension 22: 577-583.
30. Nguyen NC, Taalab K, Osman MM, (2010). Decreased blood flow with increased metabolic activity: a novel sign of pancreatic tumor aggressiveness. Clin Cancer Res 16: 367; Author reply 567.
31. Novak I, (2008). Purinergic receptors in the endocrine and exocrine pancreas. Purinergic Signal 4: 237-253.
32. Ralevic V, Burnstock G, (1998). Receptors for purines and pyrimidines. Pharmacol Rev 50: 413-492.
33. Rayment SJ, Ralevic V, Barrett DA, Cordell R, Alexander SP, (2007a). A novel mechanism of vasoregulation: ADP-induced relaxation of the porcine isolated coronary artery is mediated via adenosine release. FASEB J 21: 577-585.
34. Rayment SJ, Latif ML, Ralevic V, Alexander SP, (2007b). Evidence for the expression of multiple uracil nucleotide-stimulated P2 receptors coupled to smooth muscle contraction in porcine isolated arteries. Br J Pharmacol 150: 604-612.
35. Roberts RE, Kendall DA, Wilson VG, (1999). α2-Adrenoceptor and NPY receptor-mediated contractions of porcine isolated blood vessels: evidence for involvement of the vascular endothelium. Br J Pharmacol 128: 1705-1712.
36. Robichaud J, Fournier JF, Gagne S, Gauthier JY, Hamel M, Han Y, et al. (2011). Applying the pro-drug approach to afford highly bioavailable antagonists of P2Y(14). Bioorg Med Chem Lett 21: 4366-4368.
37. Satoh A, Shimosegawa T, Satoh K, Ito H, Kohno Y, Masamune A, et al. (2000). Activation of adenosine A1-receptor pathway induces edema formation in the pancreas of rats. Gastroenterology 119: 829-836.
38. 14 receptor in murine T-lymphocytes. Br J Pharmacol 146: 435-444.
39. 14 receptor in human neutrophils. Eur J Pharmacol 543: 166-173.
40. 14 receptor promotes Rho-mediated signalling and chemotaxis in human neutrophils. Am J Physiol Cell Physiol 303: C490-C498.
41. 14) and increase intracellular calcium in response to its agonist, uridine diphosphoglucose. J Immunol 171: 1941-1949.
42. Umapathy NS, Hick RT, Yu Y, Verin AD, (2010). Functional expression of the purinergic receptor P2Y14 in the human lung microvascular endothelial cells (HLMVEC). FASEB J 24 (Meeting Abstract Supplement): 111.9.
43. Verin A, Zemskov E, Umapathy N, Lucas R, (2011). P2Y receptors as regulators of lung endothelial barrier integrity. J Cardiovasc Dis Res 2: 14-22.
44. 12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels. Arterioscler Thromb Vasc Biol 24: 1810-1815.
45. Wong SL, Leung FP, Lau CW, Au CL, Yung LM, Yao X, et al. (2009). Cyclooxygenase-2-derived prostaglandin F2alpha mediates endothelium-dependent contractions in the aortae of hamsters with increased impact during aging. Circ Res 104: 228-235.